Comments

Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients — 4 Comments

  1. These are some outstanding reults for those of us who have failed with newer DAAs and until now had nothing to fall back on.

  2. It is still imperative for anyone who has failed an NS5a to get “resistance testing”. Reason being, as shown above there where still 10 of these patients that failed to SVR.
    The subset data will show which resistant mutations were studied and it will be intersesting to see if there is a further problem with ceratain mutations.
    Rod

    • Good point, we will learn a lot more when data is released at AASLD’s Liver Meeting in November. Stay Tuned!